Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Insulet Presents Pivotal Extension Data for Preschool Children and Other Omnipod® 5 System Clinical Research at American Diabetes Association 82nd Scientific Sessions ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery System … [Read more…]

Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech

Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval LOS ANGELES–(BUSINESS WIRE)–Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced today that, assuming satisfaction of the conditions to the closing of its pending business combination with Alvotech Holdings S.A. and Alvotech (“Topco”) (the “Business Combination”), including approval of the … [Read more…]

Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not appropriately address the U.S. Food and Drug Administration’s questions about the benefit-risk profile of Reblozyl … [Read more…]

Avivagen Provides Second Update on Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”) announces that the TSX Venture Exchange has granted a second extension of up to 30 days for completion of the balance of the Company’s previously announced non-brokered private placement of … [Read more…]

Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity

— Largest Analysis Examining Use of CAR T-cell Therapy Across Race and Ethnicity — — Black or African American Patients Experienced Longer Time from Diagnosis to Infusion Compared to White Patients, Possibly Impacting Overall and Complete Response Rates; More Study Warranted — — Clinical Trials of Yescarta in the U.S. and Real-World Use from CIBMTR … [Read more…]

ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma

– Children’s Oncology Group (COG) to Present Data from Investigator-sponsored Study at 59th American Society of Clinical Oncology (ASCO) Annual Meeting – – Phase 3 Clinical Trial of ADCETRIS Combination Therapy Demonstrated a 59% Reduction in Risk of Disease Progression or Relapse, Second Malignancy or Death vs. Standard of Care – – Data Supported Seagen’s … [Read more…]

MarinHealth CEO David Klein, MD, Featured Speaker at San Francisco Business Times’ “Future of Healthcare” Event on Tuesday, June 7

Dr. Klein to Discuss Trends and Innovations Shaping the Industry with Fellow Panelists from UCSF, Hill Physicians Medical Group, Kaiser, Anthem, Carbon Health, and Modern Health   GREENBRAE, Calif.–(BUSINESS WIRE)–MarinHealth today announced that CEO David Klein, MD, MBA, will be speaking at the San Francisco Business Times’ upcoming event on the Future of Healthcare, which … [Read more…]

Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights

Company’s multivariate blood-based test can serve as a quantitative and objective tool to evaluate an individual patient’s level of disease activity as well as overall disease activity of a clinic’s population MENLO PARK, Calif.–(BUSINESS WIRE)–Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis … [Read more…]

Call for Presentations Open for the 2022 DeviceTalks West Conference & Expo

We’d like to see engineers, entrepreneurs, manufacturers, researchers, and others contribute their lessons and experiences to our expanded DeviceTalks West event. SANTA CLARA, Calif.–(BUSINESS WIRE)–#medical—DeviceTalks West, returning from a three-year hiatus to the Santa Clara Convention Center on October 19-20, will offer an expanded program for medical device developers, executives, investors and entrepreneurs — including … [Read more…]